Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting Video, How_Do_We Know It's Not Photoshop?
It might not be photoshop, but it could be
a complete hoax filmed at a military base
sound stage. It might only be clever editing.
There was never anyone else in the frame
with Lanza at the same time. And look
at all the shadows. There's something there.
And come on, those mouse pictures are only
one tiny picture. Where's the whole roll of film
and and all the control pictures?
And what about all the mice with poor
circulation that didn't get hemangioblast
injections. It's all probably placebo effect.
I mean get real.
If any of this was remotely "real",
wouldn't the market be skyrocketing now?
HighOfTheYear First Week Of Jan, ForSecond Year InARow
Just Option Awards, tommorrow will probably be disappointing
just some cage rattling, the share price isn't budging,
if there is good news, it will have been a complete surprise
January 2nd remains the high for the year,
distant in time and price
this is a dreadful year, which is following and even
more dreadful year
It's been good if the shares are free
The SlowBall Treatment Is Increasing Value Of Ocata
If Ocats is getting FDA fast track,
what the heck is the slow track?
After a certain amount of time, people
will wake up and notice the bureaucrats
dragging their feet. Then there are inquiries,
and FBI people, and firings.
Then your education, and all that time, is worthless.
And meanwhile, more people have discovered Ocata.
Phase 1 accidentally showed a little too much
of what RPE therapy can do.
People will eventually decode the weasel words,
"efficacy signal" into IT WORKS.
Phase 1 halted macular degeneration.
And a halted dry form macular degeneration,
prevents wet form macular degeneration.
Ocata Could Potentially Cure 90% Of Legal Blindness
Wet macular degeneration accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness.
http://www.brightfocus.org/macular/about/understanding/facts.html
Wet macular degeneration is usually preceded by the dry form of the disease. This wet form occurs when the Bruch’s membrane begins to break down,
usually near drusen deposits, and new blood vessels grow. This growth is called neovascularization. These vessels are very fragile and can leak fluid and blood, resulting in scarring of the macula and the potential for rapid, severe damage.
http://www.brightfocus.org/docs/fact-sheets-in-pdf-format/macular_degeneration_frequently_asked_questions.pdf
Eylea is for wet macular degeneration only, and sales
are skyrocketing.
Tarrytown, New York-based Regeneron said it expected net sales of Eylea to be 25 percent to 30 percent higher this year than in 2014, when the eye drug raked in global sales of $1.74 billion.
http://www.reuters.com/article/2015/02/10/regeneron-pharm-results-idUSL4N0VK52620150210
Ocata's Share Count is: 35,667,442
And 1 billion of market cap represents
a share price of $28 dollars.
This is the likely starting point of a buyout.
We'll see.
Tiny, Tiny Share Count!
100% Safe Phase 1 Success
Strong Unexpected Efficacy Signal
Patents Galore
What's Ocata's Buyout Value With Phase1, Patents, Efficacy?
100% Safe Phase 1 Success
Strong Unexpected Efficacy Signal
Patents Galore
What's the high/low on a possible buyout?
All of the various types of macular degeneration
seem to be an unmet need.
All the technology for producing fully differentiated
cells, along with the purification process to
nearly 100% pure differentiated cells,
seems to be completely new, and novel.
Buyouts similar must have occurred before,
does anyone have any ideas?
After June 17 the_new_52_week low of 4.95
will 'rollover', and jump up to 5.85.
Rising lows is one half of a bull market.
The FDA special protocol is the next major event.
This is out of Ocata's control in some ways.
These guys are very careful. These guys spend
a third of their life getting PHDs, and one big
mistake ends their careers. So it's not surprising
that it takes a while.
It may come this quarter or this year,
but the FDA SPA is coming.
Time is on Ocata's side here. As the data rolls
in it adds value. As the patents roll in it adds
value. As the number of institutional buyers
increases, it adds value. As time passes the
patients story reaches more and more people,
which ultimately adds value.
wiki
A Special Protocol Assessment (SPA) is a declaration from the Food and Drug Administration that an uncompleted Phase III trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval.
Is the upcoming conference call available online?
Is there an ir.link somewhere.
I'm astonished if it's not online somewhere?
The company will host a conference call at 5:00 p.m. Eastern time to discuss the financial results. If you would like to participate in the call, please dial-in approximately 10 minutes prior to the start time, and ask to join the Organovo Holdings, Inc. conference call. The dial-in info is as follows:
US Toll Free:
1-888-243-4451
International Toll:
1-4120542-4135
A replay will be made available one hour following the live call and remain available for 30 days. To access the replay, the dial-in info is as follows:
US Toll Free:
1-877-344-7529
International Toll:
1-412-317-0088
Canada Toll Free:
855-669-9658
Replay Access Code:
10066930
BTW, nice video, if you havent seen it
Organovo Company
www.youtube.com/watch?v=Ab3omYH8KEk
'remote'-probably means based remotely, like France?
or not based at the home office.
It's all good.
Crude Spot Price Down -49.22% From Last Year
What more can you say? You figure it out.
Mar 2015 Average Crude Oil Spot Price at 52.83
down from 104.04 one year ago.
This is a change of -49.22% from one year ago.
The Jefferies Conference Is Spooking The Shorts
and it's a 4 day event!!!
The Shorts are gonna need new shorts. heh!
If you've endured the 3.29 level,
you can handle this.
Any deal announcements will make the
shorts even more toasty!
Lovely! This is lovely ground for a fight General!
RPE Therapy Works!!! Verifiably SAFE, 42 Times!!!
It's not accurate to say Ocata has nothing.
PW: If We Replicate The Data (Another 42 Times!)
PW:
7may15, CC, (final 90 seconds,
talking about RPE Therapy)
"If we even so much as replicate
the data in the Lancet,
then we've transformed this therapy now,
into a very meaningful therapy,
I believe, for the future."
Notes:
When PW refers to "the data in the Lancet",
he is talking about the ignored, belittled,
and lied about,
phase 1 | phase 2A, RESULTS.
they could only detect hand motion.
Within a few days
they could actually start to see and count fingers
-Lanza April 27, 2015
Except for one patient,
virtually all of the patients
either improved or stabilized
-Lanza April 27, 2015
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
( No one expected it would ONLY take a FEW DAYS, !!! )
( 42 patients treated now )
Key Points:
All of the patients either improved of stabilized
RPE therapy is repeatable and verified 42 times now
The speed of initial vision recovery is remarkable.
It's similar to the time for healing a scratch.
Bottom Line:
Ocata is the Premier Regenerative
Ophthalmology Company, on Earth.
PW: If We Replicate The_Data_In The Lancet...
PW:
7may15, CC, (final 90 seconds, talking about RPE Therapy)
"If we even so much as replicate
the data in the Lancet,
then we've transformed this therapy now,
into a very meaningful therapy,
I believe, for the future."
Notes:
When PW refers to "the data in the Lancet",
he is talking about the ignored, belittled,and lied about,
phase 1 | phase 2A, RESULTS.
A lot of heavy hitters at tomorrows's conference.
Opportunities to compare notes, plan, make deals.
Announcing the FDA Special Protocol Assessment
will blow things wide open!
wiki
A Special Protocol Assessment (SPA) is a declaration from the Food and Drug Administration that an uncompleted Phase III trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval.
Organovo Holdings, Inc. (NYSE MKT: ONVO; " Organovo "), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced today that the company will present at an upcoming investor event, the Jeffries 2015 Healthcare Conference, to be held in New York , June 1 – 4, 2015. Keith Murphy , Chairman and Chief Executive Officer, will deliver a company...
press release
http://ir.organovo.com/news/press-releases/
What's happened in the 3D printing stocks dragged ONVO
into the vortex.
DDD is off -80%
ONVO is off about -75%
The upcoming ONVO 10K will hit the shorts hard if it
reveals a robust order book, indicating a growing
revenue stream.
I've never looked at ONVO as only a 3D printer,
but more of a biotech in drug diagnostics.
ONVOs liver test product is way ahead of everyone
else. And the competition may never duplicate
it. ONVO has taken the idea of 3D printing
into an area that is not easily duplicated,
if at all.
This is not recognized.
The market doesn't seem to think ONVO
is anything more than a 3D printer.
We'll now see which is right.
Even DDD is unfairly sold off. I think it's
foolhardy to think HP or anyone will
duplicate DDD technology, immediately!
Do you think people will go with the
tried and true, or the cheap rip off,
when printing their jet engine parts?
I Like Ocata Because Their RPE Therapy Works!!! Real_Good!
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
they could only detect hand motion.
Within a few days
they could actually start to see and count fingers
-Lanza April 27, 2015
Except for one patient,
virtually all of the patients
either improved or stabilized
-Lanza April 27, 2015
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
( No one expected it would ONLY take a FEW DAYS, !!! )
( 42 patients treated now )
Both Eylea And Lucentis Received BreakThrough Status
Both are drugs for Wet AMD.
Both are made obsolete by Ocata RPE Therapy.
Eylea and Lucentis market cap now belongs to Ocata.
The FDA is keen on retinopathy treatments.
The FDA has already signed off on stem cells,
by approving Ocata's Phase 1|2A trials,
which are completed and very successful.
Most significantly, the EMA, the Europeans, have
ALREADY approved a Phase 2 Pivotal trial
for Ocata's RPE Thearapy.
It would be a disaster for the FDA
to force Ocata to move to Europe,
where they are already free to produce.
Post Up List, the high is 8.39, the low 5.98
It's only been on the NSDQ for 3 months,
and HUGE progress has been made in this time.
It doesn't look like it will get cheaper than this.
The EMA has ALREADY approved SMD phase 2 Pivotal.
http://ir.ocata.com/press-releases/detail/2754/ocata-therapeutics-receives-regulatory-guidance-from
A pivotal trial can refer to a clinical trial or study intended to provide evidence for a drug marketing approval, e.g. by the US FDA. Phase III trials are assumed to be pivotal so the phrase is often used for the rare pivotal phase II trials.
The EMA, OR European Medicines Agency is
roughly parallel to the U.S. FDA, but without FDA-style centralization, the European Medicines Agency was set up in 1995 and is based in London, the EMA is the core scientific advisory committee responsible for approving drugs in the European Union.
Ocata can begin phase 2 pivotal at ANY time
in Europe! This is hugely important. They could
move to Europe, finalize their product, RPE Therapy,
and fly people from America to Europe for treatment.
( Or put a clinic in Bermuda !!! , or the Virgin Isle )
I Thought L'Oreal Was A Lipstick Company
But the more I read it, it looks like a
high tech company that happens
to sell makeup.
This company is amazing.
RPE Therapy Works! It's Good For Your Macula!
You still have to open your eyes yourself though!
Once again, the Reverse Split was enormously
important. There were no institutions before it.
The reverse split made the uplist to the NSDQ
possible in February. The up list has now
brought us 28 (TWENTY-EIGHT), new institutions!
From 2 to 30!!!
Ocata is being integrated into the broader market
place. It's transitioning from a research entity
to a financial entity. And institutions are
stepping up.
It looks as though this data is reported each
quarter, and it seems to trickle in as well.
This is a nice start! There are some recognizable
names and it shows some interest.
Making the transition to a financial entity,
is also important for raising money. The
participation of these institutions makes
the prospect of raising money much more
favorable now.
FDA guidance, when it finally arrives,
might bring some share price interest,
and break us out of the 6 to 7.50 range
we've been locked into these past
7 or 8 months.
The share count is only 35,667,442
as of 30 Apr 2015, from the 10K.
With good news, this tiny float could
cause an exaggerated move.
That good news, might be FDA guidance.
11 Institutions with More the 10,000 shares,
30 Total, 28 New on 3/31/15
SUSQUEHANNA INTERNATIONAL GROUP, LLP
03/31/2015__61,043 shares
MORGAN STANLEY
03/31/2015__56,171
MILLENNIUM MANAGEMENT LLC
03/31/2015__51,840
KCG HOLDINGS, INC.
03/31/2015__27,676
BLUECREST CAPITAL MANAGEMENT LTD
03/31/2015__25,400
JANE STREET GROUP, LLC
03/31/2015__21,517
GOLDMAN SACHS GROUP INC
03/31/2015__19,000
COMMONWEALTH EQUITY SERVICES, INC
03/31/2015__17,421
MARK SHEPTOFF FINANCIAL PLANNING, LLC
03/31/2015__17,262
VANGUARD GROUP INC
03/31/2015__14,300
ALETHEA CAPITAL MANAGEMENT, LLC
03/31/2015__11,000
The L'Oreal Deal Could Be Bigger Than Expected
Maybe they'll help ONVO take their
technology to the nanoscale realm !!!
The L'Oréal Group is a French cosmetics and beauty company, headquartered in Clichy, Hauts-de-Seine.[2] It is the world's largest cosmetics company, and has a registered office in Paris.[3] It has developed activities in the field of cosmetics, concentrating on hair colour, skin care, sun protection, make-up, perfumes and hair care, the company is active in the dermatology, toxicology, tissue engineering, and biopharmaceutical research fields and is the top nanotechnology patent-holder in the United States.
http://en.wikipedia.org/
FDA_Endpoints_ComingForPhase2 Pivotal! Because, RPE Therapy Works!
Ocata doesn't need ANY money until things
are squared away with the FDA. The
running out of funds talk, is running out
of steam. It's alarmist nonsense that
doesn't magically become true because
it gets repeated, ad infinitum.
The US FDA is functionally EQUIVALENT to
the European Medicines Agency, or EMA.
It's not a big stretch to predict that the FDA
will arrive at a solution similar to the EMA.
The EMA has ALREADY approved SMD phase 2 Pivotal.
http://ir.ocata.com/press-releases/detail/2754/ocata-therapeutics-receives-regulatory-guidance-from
A pivotal trial can refer to a clinical trial or study intended to provide evidence for a drug marketing approval, e.g. by the US FDA. Phase III trials are assumed to be pivotal so the phrase is often used for the rare pivotal phase II trials.
Dr. Anglade CC 7May2015
"This pivotal trial for SMD..."
"The goals of the study are to evaluate the safety
and efficacy of RPE Cellular therapy using EndPoints
that are acceptable to regulatory bodies on
both sides of the Atlantic."
"Outcome parameters will include assessment of
visual function as well as anatomic changes"
So, let's put this into plain language.
Ocata is asking the FDA to define exactly what
results they require to grant approval, BEFORE,
they begin the phase 2 pivotal trial.
They call these results "endpoints".
And they will be enumerated in the SPA,
(Special Protocol Assessment).
These results will be an eye test, and high
resolution OCT scans, or "assessment of
visual function as well as anatomic changes".
A phase 2 pivotal eliminates the phase 3 trial.
The "endpoints" will satisfy the FDA and EMA,
or "both sides of the Atlantic."
wiki
A Special Protocol Assessment (SPA) is a declaration from the Food and Drug Administration that an uncompleted Phase III trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval.
RPE Therapy Works! This Is An Unchallenged FACT!
Lanza and his colleagues were also the first to demonstrate that nuclear transplantation could be used to reverse the aging process and to generate immune-compatible tissues, including the first organ tissue-engineered from cloned cells. One of his greatest early achievements came from his demonstration that techniques used in preimplantation genetic diagnosis could be used to generate human embryonic stem (hES) cells without embryonic destruction. He and colleagues have also succeeded in differentiating human pluripotent stem cells into retinal (RPE) cells, and has shown that they provide long-term benefit in animal models of vision loss. Using this technology some forms of blindness may be curable, including macular degeneration and Stargardt disease, a currently untreatable form eye disease that causes blindness in teenagers and young adults. Lanza’s company (ACT) received FDA approval to begin clinical trials using them to treat degenerative eye diseases. These two clinical trials began in July 2011. Recently, ACT received similar approval for the first human embryonic stem cell trial in Europe. Surgeons at Moorfields Eye Hospital in London will inject healthy retinal cells into the eyes of patients with Stargardt’s macular dystrophy, hoping to slow, halt or even reverse the effects of the disease. The first person received the embryonic stem cell treatment earlier this year. The patient reports improved vision in the eye treated with the cells, which The Guardian said “represents a huge scientific achievement.”
Dr. Lanza and his colleagues published the first-ever report of human embryonic stem cells transplanted into human patients. Two clinical studies were initiated to establish the safety and tolerability of subretinal transplantation of hESC-derived RPE in patients with Stargardt’s macular dystrophy and dry age-related macular degeneration (AMD). After surgery, evidence confirmed cells had attached and continued to persist during the study. There were no signs of tumorigenicity or rejection in either patient. The patients who received the stem cell transplants say their lives have been transformed by the experimental procedure. During the observation period visual acuity improved from hand motions to 20/800 (and improved from 0 to 5 letters on the standard visual acuity chart) in the study eye of the patient with Stargardt’s disease, and vision also seemed to improve in the patient with dry AMD. One of the patients no longer needs a large magnifying glass to read and can reportedly thread a needle and has begun to go shopping on her own. The future therapeutic goal will of these studies will be to treat patients earlier in the disease processes, potentially increasing the likelihood of visual rescue.
http://www.robertlanza.com/who-is-robert-lanza/
RPE Therapy Works! It's Like A Retina Transplant
they could only detect hand motion.
Within a few days
they could actually start to see and count fingers
-Lanza April 27, 2015
Except for one patient,
virtually all of the patients
either improved or stabilized
-Lanza April 27, 2015
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
( No one expected it would ONLY take a FEW DAYS, !!! )
( 42 patients treated now )( Failure Seems to be quite RARE ! ( one patient ! ) )
Phase 1 | 2A was BETTER than anyone expected.
The EMA has ALREADY approved SMD phase 2 Pivotal.
http://ir.ocata.com/press-releases/detail/2754/ocata-therapeutics-receives-regulatory-guidance-from
A pivotal trial can refer to a clinical trial or study intended to provide evidence for a drug marketing approval, e.g. by the US FDA. Phase III trials are assumed to be pivotal so the phrase is often used for the rare pivotal phase II trials.
PW:
7may15, CC, (final 90 seconds, talking about RPE Therapy)
"If we even so much as replicate
the data in the Lancet,
then we've transformed this therapy now,
into a very meaningful therapy, I believe, for the future."
Notes:
When PW refers to "the data in the Lancet",
he is talking about the ignored, belittled,and lied about, phase 1 | phase 2A, RESULTS.
We can, ... take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells ... if they have macular degeneration
Principal Investigator: Steven Schwartz, MD
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
Slide 16, Dr. Anglade: "The retina is basically a
10 cell layer thick tissue. The very bottom is
a single cell layer called the pigment epithelium.
And that's the tissue we're transplanting."
And what this means:
What we did is transplant the cells into patients who
have a disease where those particular cells are dying;
And we replaced those dying tissues with new tissue
that's derived from these stem cells. In a way
it's a retinal transplant. - Dr Steven Schwartz, UCLA
Roadshow 1.0
RPE Therapy Works! ALL PATIENTS Improved or Stabilized
they could only detect hand motion.
Within a few days
they could actually start to see and count fingers
-Lanza April 27, 2015
( I bet they didn't expect it would ONLY take a
FEW DAYS, the retail market hasn't noticed this !!! )
Except for one patient,
virtually all of the patients either improved or stabilized
-Lanza April 27, 2015
( 42 patients treated now )
( Failure Seems to be quite RARE ! ( one patient ! ) )
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
Phase 1 | 2A was BETTER than anyone expected.
The EMA has ALREADY approved SMD phase 2 Pivotal.
http://ir.ocata.com/press-releases/detail/2754/ocata-therapeutics-receives-regulatory-guidance-from
A pivotal trial can refer to a clinical trial or study intended to provide evidence for a drug marketing approval, e.g. by the US FDA. Phase III trials are assumed to be pivotal so the phrase is often used for the rare pivotal phase II trials.
PW:
7may15, CC, (final 90 seconds,
talking about RPE Therapy)
"If we even so much as replicate the data in the Lancet,
then we've transformed this therapy now, into a very
meaningful therapy, I believe, for the future."
Notes:
When PW refers to " the data in the Lancet",
he is talking about the ignored, belittled,
and lied about, phase 1 | phase 2A.
RPE Therapy Works! IN_A_Few_Days, I Could See!
they could only detect hand motion.
Within a few days
they could actually start to see and count fingers
-Lanza April 27, 2015
( I bet they didn't expect it would ONLY take a
FEW DAYS, the retail market hasn't noticed this !!! )
Except for one patient, virtually all of the patients either improved or stabilized
-Lanza April 27, 2015
( 42 patients treated now )
( Failure Seems to be quite RARE ! (one patient!!!) )
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
Phase 1/Phase 2A was BETTER than anyone expected.
The EMA has ALREADY approved SMD phase 2 Pivotal.
http://ir.ocata.com/press-releases/detail/2754/ocata-therapeutics-receives-regulatory-guidance-from
A pivotal trial can refer to a clinical trial or study intended to provide evidence for a drug marketing approval, e.g. by the US FDA. Phase III trials are assumed to be pivotal so the phrase is often used for the rare pivotal phase II trials.
PW:
7may15, CC, (final 90 seconds), talking about RPE Therapy
"If we even so much as replicate the data in the Lancet,
then we've transformed this therapy now, into a very
meaningful therapy, I believe, for the future."
Notes:
When PW refers to " the data in the Lancet", he is
talking about the ignored and belittled
phase 1 | phase 2A.
Top 5 Institution Share Holders
State Street Corp,___________________3,598,468, 12/31/2014
Vanguard Group, Inc.,________________2,253,795, 12/31/2014
Think Investments LLC,_______________1,380,997, 12/31/2014
Fidelity Mgt and Research Company,____1,305,100, 12/31/2014
BlackRock Fund Advisors,_____________1,682,091, 03/31/2015
The entire list is pretty impressive. It looks like year end 2014
was the entry point. Let's hope they don't decide to throw in
the towel, or get stress from some other area.
RPE Therapy Works! Breakthrough Status Seems Very Likely!
they could only detect hand motion.
Within a few days
they could actually start to see and count fingers
-Lanza April 27, 2015
( I bet they didn't expect it would ONLY take a
FEW DAYS, the retail market hasn't noticed this !!! )
Except for one patient, virtually all of the patients either improved or stabilized
-Lanza April 27, 2015
( 42 patients treated now )
( Failure Seems to be quite RARE ! (one patient!!!) )
Phase 1/Phase 2A was BETTER than anyone expected.
The EMA has ALREADY approved SMD phase 2 Pivotal.
http://ir.ocata.com/press-releases/detail/2754/ocata-therapeutics-receives-regulatory-guidance-from
A pivotal trial can refer to a clinical trial or study intended to provide evidence for a drug marketing approval, e.g. by the US FDA. Phase III trials are assumed to be pivotal so the phrase is often used for the rare pivotal phase II trials.
This is a real wildcard! Everyone is waiting for the FDA
to demonstrate that they understand what is happening.
If RPE therapy brings a patient back from blindness to
seeing fingers on a hand, and after only a FEW days!,
that's remarkable, and an absolute GAME CHANGER!
Let's see what Dr. Lanza says today at
The Common Good. This guy is another Tesla in
the medical field. He is a supremely good man.
RPE Therapy Works! Creative Destruction, InProgress, Of Eylea!
they could only detect hand motion.
Within a few days
they could actually start to see and count fingers
-Lanza April 27, 2015
( I bet they didn't expect it would ONLY take a
FEW DAYS, the retail market hasn't noticed this !!! )
Except for one patient, virtually all of the patients either improved or stabilized
-Lanza April 27, 2015
( 42 patients treated now )
( Failure Seems to be quite RARE ! (one patient!!!) )
Eylea dosage requires 6, SIX!!!, Eye Jabs, EACH year, FOR LIFE !!!
RPE Thearpy from Ocata requires, 1, ONE!!!, injection ONCE !!!
Smell The Coffee, and Smell The Destruction,
creative destruction, that is.
Short REGN, Buy OCAT
Do it now! Do your own DD.
DEFINITION of 'Creative Destruction'
A term coined by Joseph Schumpeter in his work entitled "Capitalism, Socialism and Democracy" (1942) to denote a "process of industrial mutation that incessantly revolutionizes the economic structure from within, incessantly destroying the old one, incessantly creating a new one."
RPE Therapy Works! All Patients Improved or Stabilized
they could only detect hand motion.
Within a few days
they could actually start to see and count fingers
-Lanza April 27, 2015
( I bet they didn't expect it would ONLY take a
FEW DAYS, the retail market hasn't noticed this !!! )
Except for one patient, virtually all of the patients either improved or stabilized
-Lanza April 27, 2015
( 42 patients treated now )
( Failure Seems to be quite RARE ! (one patient!!!) )
These FACTs, are times 10, more important,
than all of the EXAGGERATED problems.
And all problems are being exaggerated,
while phase 1|phase 2A is being ignored.
( 42 Patients Treated So Far )
Phase 2B will designed, AND agreed upon
to simply REPLICATE the success of PH1|PH2A.
(Last comment in the recent CC)
Completed Phase 1|Phase 2A was 42 Patients.
Planned dry-AMD Phase 2B is 60 Patients.
Half of Phase 2B will be sham injections,
so Phase 1|Phase 2A is actually larger than
the Planned Phase 2B !!!
Be Attentive !!!
ALL BUT ONE !
...Just a 'tiny' phase 2B to go, heh!, LOL, ROTFLOL
If the FDA doesn't get on the ball, OCAT,
can ditch them and go to the EMA,
which has already provided WRITTEN
guidance for SMD PH2 PIVOTAL.
http://ir.ocata.com/press-releases/detail/2754/ocata-therapeutics-receives-regulatory-guidance-from
That would be ruthless!
This would make WAVES at the FDA,
and bring embarrassment AND ATTENTION
to ANOTHER American FAILURE !!!
( LET THE BUREAUCRATS GET SEA SICK !!! )
( Ocata could use the attention !!! )
( IT'S NOT HYPE FOLKS, IT'S REALITY,
AND SUCCESS )
------------------------------------------------
( HALTING THE DISEASE - IS SUCCESS )
------------------------------------------------
( IMPROVED VISION - IS SUCCESS )
------------------------------------------------
( IT'S REALITY !!! )
( only 2 Weeks Ago )
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
(Dr. Lanza talking about COMPLETED RPE Ph1|Ph2A)
(The first SMD patient referred to is Cathy from the
Charlie Rose program below)
(Cathy, could only detect hand motion!!!,
now she can use her computer,
and see details on her carved furniture!
And, with one good eye,
she can re-apply for a driver's license !!!)
During that follow up period, we actually found in both the SMD and the AMD patients that they had significant overall visual improvement in the treated eyes. Except for one patient, virtually all of the patients either improved or stabilized during that time period. By contrast, the untreated eyes did not show similar improvement in their visual acuity. And this just shows you an overview of the results, so this is the median visual acuity over baseline. So what you are seeing here with the dotted line is the untreated fellow eye. We treated just one eye, so the untreated eye you can see at 6 months and one year, there was no improvement in vision during that time period. By contrast, the eye that we treated with the RPE cells, here you can see that's the solid blue line. There were 15 letters of improvement in these patients. That represents about three lines of visual improvement in these patients. That's a double in visual angle and is generally considered clinically significant. And many of these patients, for instance, they could only detect hand motion. Within a few days they could actually start to see and count fingers. Eventually they could start reading letters on the visual acuity chart and indeed the first SMD patient that we had that could only detect hand motion, now is out over two years and can read 4 lines, 19 letters on the visual acuity chart, and she can use her computer. People can now go to the mall on their own, so this has made a significant difference in the quality of life for many of these patients.
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
Cathy's Story
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
RPE Therapy Works! This FACT Trumps Everything Else
they could only detect hand motion. Within a few days they could actually start to see and count fingers-Lanza
This FACT, is times 10, more important,
than all of the EXAGGERATED problems.
And all problems are being exaggerated,
while phase 1|phase 2A is ignored.
Phase 2B will designed, AND agreed upon
to simply REPLICATE the success of PH1|PH2A.
This is what's being discussed with the FDA
now. (Last comment in the recent CC)
If the FDA doesn't get off the ball, OCAT,
can ditch them and go to the EMA,
which has already provided WRITTEN
guidance for SMD PIVOTAL.
That would be ruthless!
(This is the reality, below. People won't discuss
this because it's immediately branded as HYPE!)
(IT'S NOT HYPE FOLKS, IT'S REALITY, AND SUCCESS)
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
(Dr. Lanza talking about COMPLETED RPE Ph1|Ph2A)
(The first SMD patient referred to is Cathy from the Charlie
Rose program below)
(Cathy could only detect hand motion!!!, now she can use her computer, and see details on her carved furniture!)
During that follow up period, we actually found in both the SMD and the AMD patients that they had significant overall visual improvement in the treated eyes. Except for one patient, virtually all of the patients either improved or stabilized during that time period. By contrast, the untreated eyes did not show similar improvement in their visual acuity. And this just shows you an overview of the results, so this is the median visual acuity over baseline. So what you are seeing here with the dotted line is the untreated fellow eye. We treated just one eye, so the untreated eye you can see at 6 months and one year, there was no improvement in vision during that time period. By contrast, the eye that we treated with the RPE cells, here you can see that's the solid blue line. There were 15 letters of improvement in these patients. That represents about three lines of visual improvement in these patients. That's a double in visual angle and is generally considered clinically significant. And many of these patients, for instance, they could only detect hand motion. Within a few days they could actually start to see and count fingers. Eventually they could start reading letters on the visual acuity chart and indeed the first SMD patient that we had that could only detect hand motion, now is out over two years and can read 4 lines, 19 letters on the visual acuity chart, and she can use her computer. People can now go to the mall on their own, so this has made a significant difference in the quality of life for many of these patients.
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
Cathy's Story
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
We're Gonna Cure Blindness, And Give You A_Lolly_Pop
How do you top curing blindness?
You cannot.
To those who are disappointed with yesterday's CC,
that is the question.
PW made it very clear,
if phase 2B EQUALS,
I SAY AGAIN, EQUALS !!!
what has already occured in phase 1 | phase 2A,
phase 2B will be an unqualified SUCCESS !!!
You cannot top reality.
And you cannot help those who ignore reality.
Period.
It's_Unwise To_Do Anything Until RPE Is Done
What if something went wrong? The risk isn't
worth it.
RPE is coming along brilliantly !
When a person can go from only seeing hand movement,
to being able to count fingers on the hand,
IN A FEW DAYS,
that's brilliant!
Why mess with this, with a second program until
this is safely completed? This therapy is new,
many people don't even think it's 'real'.
The talk about platelettes and the bio-reactor chip
is very interesting though. This looks like another
low hanging fruit situation. 5 day span until spoilage,
human donors the only source.
This is a huge unmet need. Or build it and they
will come thing.
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
(Dr. Lanza talking about COMPLETED RPE Ph1|Ph2A)
(The first SMD patient referred to is Cathy from the Charlie
Rose program below)
(Cathy could only detect hand motion!!!, now she can use her computer, and see details on her carved furniture!)
During that follow up period, we actually found in both the SMD and the AMD patients that they had significant overall visual improvement in the treated eyes. Except for one patient, virtually all of the patients either improved or stabilized during that time period. By contrast, the untreated eyes did not show similar improvement in their visual acuity. And this just shows you an overview of the results, so this is the median visual acuity over baseline. So what you are seeing here with the dotted line is the untreated fellow eye. We treated just one eye, so the untreated eye you can see at 6 months and one year, there was no improvement in vision during that time period. By contrast, the eye that we treated with the RPE cells, here you can see that's the solid blue line. There were 15 letters of improvement in these patients. That represents about three lines of visual improvement in these patients. That's a double in visual angle and is generally considered clinically significant. And many of these patients, for instance, they could only detect hand motion. Within a few days they could actually start to see and count fingers. Eventually they could start reading letters on the visual acuity chart and indeed the first SMD patient that we had that could only detect hand motion, now is out over two years and can read 4 lines, 19 letters on the visual acuity chart, and she can use her computer. People can now go to the mall on their own, so this has made a significant difference in the quality of life for many of these patients.
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
THIS IS A SLAM-DUNK-A-DUNK OF BURNIN' LOVE !!!
Yesterday's Action After The PR Bodes Well
The Loreal PR sent the shorts goons into
a panic, until the PR was digested as old
news.
This means news of deals will change the game.
And there must be deals we don't know about
if the 80% number is true.
Q1 data is comin' like a train that keeps on rolling !
We know ONVO is ahead of EVERYONE in
the bioprinting realm.
As ONVO tweaks their process to use better
cell raw materials, perhaps hESC derived
liver tissue, we will see profound things
happen.
If it closes Up Today, that's Very Positive
You'll always be able to buy in the future,
but probably not this cheaply.
All the news for Ocata has been positive lately,
from last August's reverse split to last week's
confirmation of the phase 1, phase 2A data,
from Korea.
Safety has been proven, and now independently
confirmed, and this will be repeated again and
again.
Korea represents independent confirmation,
and only adds to the good news.
They have stopped recruiting for phase 2B,
which means they are getting closer to the
day when patients will start getting their injections.
It would be interesting to know how many people
were turned away from phase 2B before they
closed the doors. I bet there were millions turned
away.
We Have Ignition !
heh
Q1 Data, Will Be Here Before You KnowIt!
ONVO is looking very strong here.
This little pull back, filled a gap.
And now it looks ready to continue the rise.
Within_a_few_days_they_could...see and count fingers
they could only detect hand motion. Within a few days they could actually start to see and count fingers
A FEW DAYS...!!!!!!!!!!
This is a SLAM-DUNK.
Phase 2 will show results soon after it begins.
Get ready folks.
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
(Dr. Lanza talking about COMPLETED RPE Ph1|Ph2A)
(The first SMD patient referred to is Cathy from the Charlie
Rose program below)
(Cathy could only detect hand motion!!!, now she can use her computer, and see details on her carved furniture!)
During that follow up period, we actually found in both the SMD and the AMD patients that they had significant overall visual improvement in the treated eyes. Except for one patient, virtually all of the patients either improved or stabilized during that time period. By contrast, the untreated eyes did not show similar improvement in their visual acuity. And this just shows you an overview of the results, so this is the median visual acuity over baseline. So what you are seeing here with the dotted line is the untreated fellow eye. We treated just one eye, so the untreated eye you can see at 6 months and one year, there was no improvement in vision during that time period. By contrast, the eye that we treated with the RPE cells, here you can see that's the solid blue line. There were 15 letters of improvement in these patients. That represents about three lines of visual improvement in these patients. That's a double in visual angle and is generally considered clinically significant. And many of these patients, for instance, they could only detect hand motion. Within a few days they could actually start to see and count fingers. Eventually they could start reading letters on the visual acuity chart and indeed the first SMD patient that we had that could only detect hand motion, now is out over two years and can read 4 lines, 19 letters on the visual acuity chart, and she can use her computer. People can now go to the mall on their own, so this has made a significant difference in the quality of life for many of these patients.
Dr. Robert Lanza, UConn Stem Cell, April 27, 2015
Cathy's Story
40 minutes in, on the link below
Cathy: When I was younger I played a lot of competitive tennis, and I think when I was like in my later teens, I started playing a little more poorly. It was seeing the lines or the ball not quite as precisely, and calling the lines and stuff was a little more difficult. I woke up one morning and I looked across my room and I have a piece of furniture there, that's kind of this large armoire and it has a lot of carved detail on it, and I actually had my head to the side and I opened the operated eye and I looked at it, and for the first time I could see the detail in it, that I hadn't been able to see from the distance I was lying down. After that I just got up and I started looking at everything around the house, and looked at the grass, I mean looking at everything with one eye and then the other eye, because you know they only operated on the one eye, and I could see it a lot better than I had before, and I thought, wow, maybe there is something here that will really be working you know. It was pretty exciting.
We can, ... take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells ... if they have macular degeneration
Principal Investigator: Steven Schwartz, MD
Dr. Stephen Schwartz, UCLA and Jules Stein Institute
Charlie Rose show, 4/22/14
http://www.charlierose.com/watch/60378567
The Shorts Data is Meaningless.
New Short Data from 4/15
4/15/2015 20,594,097
80.46 shares outstanding
25.6% short percentage
Longs almost always out number shorts
by more than 3 to 1, (25% Shorts),
and this doesn't make the price go up.
Market positions don't have any effect
on the price. It may represent an opinion,
but opinions are like..., well opinions can
be wrong.
Next week we should get Q1 data,
let's wait and see what the revenue data shows.
The shorts better hope for no more 8Ks
with more deals.
The Share Price Will Explode Rendering Lincoln Irrelevant
This is the flip-side no one is looking at or imagining
might be.
Someone is trying to patiently accumulate shares.
And this is distorting the chart.
The high-low range is tightening.
And once the share price goes above $7.50,
it will either establish a new higher range or
explode upward.
Both are good.
And Lincoln won't matter at all.
It's Down 98%, Why Are You Here?
Should we believe someone is shorting
the last 2% of a 20 year dog?
If anyone takes the 98% scenerio serious,
you have to ask why?
When you ask why?
Most things melt away
rather quickly.
Like, why does anyone think 8 cells in
a lab dish is a human being?
And if you take away one cell from eight,
is that really the same as chopping
off a toddler's leg?
I don't think so.
At some point, you have to hoist the
flag of absurdity. And be done
with it. Just don't engage,
walk away.